Literature DB >> 9339683

A novel sodium channel mutation causing a hyperkalemic paralytic and paramyotonic syndrome with variable clinical expressivity.

S Wagner1, H Lerche, N Mitrovic, R Heine, A L George, F Lehmann-Horn.   

Abstract

A point mutation A4078G predicting the amino acid exchange Met1360Val in segment IV/S1 of the human muscle sodium channel alpha-subunit was identified in a family presenting features of hyperkalemic periodic paralysis and paramyotonia congenita with sex-related modification of expression. In this family, only one male member is clinically affected, presenting episodes of flaccid weakness as well as paradoxical myotonia and cold-induced weakness. Three female family members who have the same mutation show only myotonic bursts on EMG. We studied the functional defect caused by this mutation by investigating recombinant wild type (WT) and mutant sodium channels expressed in a mammalian cell line (HEK293) using the patch-clamp technique. With mutant channels, the decay of the sodium currents was two times slower than with WT, the steady-state inactivation curve was shifted by -13 mV, and recovery from inactivation was 1.5 times faster. High extracellular potassium (9 mM) did not affect channel gating. Single-channel measurements revealed prolonged mean open times and an increased number of channel reopenings. The results are remarkable with respect to the lack of complete penetrance usually seen with sodium channelopathies and the site of mutation that was formerly not thought to be involved in channel inactivation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339683     DOI: 10.1212/wnl.49.4.1018

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Periodic paralysis: understanding channelopathies.

Authors:  Frank Lehmann-Horn; Karin Jurkat-Rott; Reinhardt Rüdel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

2.  A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation.

Authors:  S Bendahhou; T R Cummins; A F Hahn; S Langlois; S G Waxman; L J Ptácek
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  Mechanisms of cold sensitivity of paramyotonia congenita mutation R1448H and overlap syndrome mutation M1360V.

Authors:  Bahram Mohammadi; Nenad Mitrovic; Frank Lehmann-Horn; Reinhard Dengler; Johannes Bufler
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

4.  Four-mode gating model of fast inactivation of sodium channel Nav1.2a.

Authors:  Tobias Huth; Johann Schmidtmayer; Christian Alzheimer; Ulf-Peter Hansen
Journal:  Pflugers Arch       Date:  2008-04-19       Impact factor: 3.657

5.  N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita.

Authors:  Qing Ke; Jia Ye; Siyang Tang; Jin Wang; Benyan Luo; Fang Ji; Xu Zhang; Ye Yu; Xiaoyang Cheng; Yuezhou Li
Journal:  J Physiol       Date:  2017-10-15       Impact factor: 5.182

6.  Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol.

Authors:  G Haeseler; M Mamarvar; J Bufler; R Dengler; H Hecker; J K Aronson; S Piepenbrock; M Leuwer
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  Voltage-dependent block of normal and mutant muscle sodium channels by 4-Chloro-m-Cresol.

Authors:  G Haeseler; M Leuwer; J Kavan; A Würz; R Dengler; S Piepenbrock
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

8.  Activation and inactivation of the voltage-gated sodium channel: role of segment S5 revealed by a novel hyperkalaemic periodic paralysis mutation.

Authors:  S Bendahhou; T R Cummins; R Tawil; S G Waxman; L J Ptácek
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

Review 9.  Sodium channelopathies of skeletal muscle result from gain or loss of function.

Authors:  Karin Jurkat-Rott; Boris Holzherr; Michael Fauler; Frank Lehmann-Horn
Journal:  Pflugers Arch       Date:  2010-03-17       Impact factor: 3.657

Review 10.  Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.